Sodium Channel Blocker Compositions and the Use Thereof

Abstract

Methods of treating or preventing chronic pain or convulsion are disclosed by administering to an animal a sodium channel blocker and at least one of gabapentin and pregabalin. Also disclosed are pharmaceutical compositions and kits for the treatment or prevention of chronic pain or convulsion.

1 - 9 . (canceled) 
   
   
       10 . A method of treating, preventing or ameliorating chronic pain, comprising administering to a patient in need thereof a first agent which is a sodium channel blocker, and a second agent selected from the group consisting of gabapentin, pregabalin, salts thereof and combinations thereof, wherein the total amount of said first agent and said second agent is effective to treat, prevent or ameliorate chronic pain. 
   
   
       11 . The method of  claim 10 , wherein said method is treating chronic pain. 
   
   
       12 . The method of  claim 10 , wherein said chronic pain is due to inflammatory pain, neuropathic pain, cancer pain, postoperative pain, or idiopathic pain. 
   
   
       13 . The method of  claim 12 , wherein said chronic pain is due to inflammatory pain, postoperative pain, osteoarthritis pain associated with metastatic cancer, trigeminal neuralgia, acute herpetic neuralgia, acute postherpetic neuralgia, diabetic neuropathy, causalgia, brachial plexus avulsion, occipital neuralgia, reflex sympathetic dystrophy, fibromyalgia, gout, phantom limb pain, or burn pain. 
   
   
       14 . The method of  claim 12 , wherein said chronic pain is due to trigeminal neuralgia. 
   
   
       15 . The method of  claim 12 , wherein said chronic pain is due to diabetic neuropathy. 
   
   
       16 . The method of  claim 12 , wherein said chronic pain is due to cancer pain. 
   
   
       17 . The method of  claim 10 , wherein said first agent and said second agent are administered substantially simultaneously. 
   
   
       18 . The method of  claim 10 , wherein said first agent and said second agent are administered separately. 
   
   
       19 . The method of  claim 10 , wherein said first agent and said second agent are administered as part of a single pharmaceutical preparation. 
   
   
       20 . The method of  claim 10 , wherein said first agent and said second agent are administered intramuscularly, wherein the dose of said second agent is about 25 mg/day to about 1600 mg/day. 
   
   
       21 . The method of  claim 11 , wherein said first agent is administered orally. 
   
   
       22 . The method of  claim 21 , wherein said first agent is carbamazepine. 
   
   
       23 . The method of  claim 22 , wherein the amount of carbamazepine is from about 50 to about 1500 mg/day. 
   
   
       24 . The method of  claim 23 , wherein the amount of carbamazepine is from about 100 to about 800 mg/day. 
   
   
       25 . The method of  claim 24 , wherein the amount of carbamazepine is from about 100 to about 600 mg/day. 
   
   
       26 . The method of  claim 25 , wherein the amount of carbamazepine is from about 100 to about 400 mg/day. 
   
   
       27 . The method of  claim 24 , wherein the amount of carbamazepine is from about 400 to about 800 mg/day. 
   
   
       28 . The method of  claim 21 , wherein said first agent is lamotrigine. 
   
   
       29 . The method of  claim 28 , wherein the amount of lamotrigine is from about 50 to about 1200 mg/day. 
   
   
       30 . The method of  claim 29 , wherein the amount of lamotrigine is from about 100 to about 600 mg/day. 
   
   
       31 . The method of  claim 30 , wherein the amount of lamotrigine is from about 100 to about 450 mg/day. 
   
   
       32 . The method of  claim 31 , wherein the amount of lamotrigine is from about 100 to about 300 mg/day. 
   
   
       33 . The method of  claim 30 , wherein the amount of lamotrigine is from about 200 to about 600 mg/day. 
   
   
       34 . The method of  claim 21 , wherein said first agent is 4-(4′-fluorophenoxy)-benzaldehyde semicarbazone. 
   
   
       35 . The method of  claim 34 , wherein the amount of 4-(4′-fluorophenoxy)benzaldehyde semicarbazone is from about 50 to about 1200 mg/day. 
   
   
       36 . The method of  claim 35 , wherein the amount of 4-(4′-fluorophenoxy)benzaldehyde semicarbazone is from about 200 to about 900 mg/day. 
   
   
       37 . The method of  claim 36 , wherein the amount of 4-(4′-fluorophenoxy)benzaldehyde semicarbazone is from about 200 to about 750 mg/day. 
   
   
       38 . The method of  claim 37 , wherein the amount of 4-(4′-fluorophenoxy)benzaldehyde semicarbazone is from about 200 to about 600 mg/day. 
   
   
       39 . The method of  claim 36 , wherein the amount of 4-(4′-fluorophenoxy)benzaldehyde semicarbazone is from about 350 to about 900 mg/day. 
   
   
       40 . The method of  claim 11 , wherein said second agent is administered orally. 
   
   
       41 . The method of  claim 40 , wherein said second agent is gabapentin. 
   
   
       42 . The method of  claim 41 , wherein the amount of gabapentin is from about 100 to about 3200 mg/day. 
   
   
       43 . The method of  claim 42 , wherein the amount of gabapentin is from about 100 to about 1800 mg/day. 
   
   
       44 . The method of  claim 43 , wherein the amount of gabapentin is from about 150 to about 900 mg/day. 
   
   
       45 . The method of  claim 43 , wherein the amount of gabapentin is from about 300 to about 1800 mg/day. 
   
   
       46 . The method of  claim 40 , wherein said second agent is pregabalin. 
   
   
       47 . The method of  claim 46 , wherein the amount of pregabalin is from about 75 to about 900 mg/day. 
   
   
       48 . The method of  claim 47 , wherein the amount of pregabalin is from 75 to about 450 mg/day. 
   
   
       49 . The method of  claim 47 , wherein the amount of pregabalin is from about 150 to about 900 mg/day. 
   
   
       50 . The method of  claim 11 , wherein said first agent is administered parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, transdermally, or buccally. 
   
   
       51 . The method of  claim 11 , wherein said second agent is administered parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, transdermally, or buccally. 
   
   
       52 . A method of treating, preventing or ameliorating chronic pain, comprising administering substantially simultaneously to a patient in need thereof a sodium channel blocker and at least one of gabapentin and pregabalin, wherein said sodium channel blocker and at least one of gabapentin and pregabalin are administered in amounts effective to treat or prevent chronic pain.